BAM
APGE

Blueshift Asset Management’s Apogee Therapeutics APGE Stock Holding History

Blueshift Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$559K Buy
4,209
+1,404
+50% +$126K 0.13% 175
2026
Q1 		$236K Buy
+2,805
New +$204K 0.07% 401

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Blueshift Asset Management's APGE Position: Q2 2026 in Review

Blueshift Asset Management increased its Apogee Therapeutics (APGE) stake by 50% in Q2 2026, buying an estimated $126K and bringing the position to 4,209 shares worth $559K. The position accounts for 0.13% of the portfolio, ranked #175.

Blueshift Asset Management first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Blueshift Asset Management held 4,209 shares of Apogee Therapeutics worth $559K as of Q2 2026.
  • Blueshift Asset Management bought 1,404 Apogee Therapeutics shares in Q2 2026, an estimated $126K.
  • Apogee Therapeutics made up 0.13% of Blueshift Asset Management's portfolio in Q2 2026, its #175 holding.
  • Blueshift Asset Management first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.